Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
